Abstract

mRNA technology has revolutionized vaccine development, offering rapid production and robust immune responses. The recent success of mRNA vaccines against COVID-19 has highlighted the potential of this platform in combating infectious diseases. Unlike traditional vaccines, which rely on inactivated pathogens or proteins, mRNA vaccines introduce messenger RNA into cells, instructing them to produce a target antigen that stimulates the immune system. This technology allows for faster vaccine development, flexibility in addressing mutating pathogens, and the ability to target diseases that have been difficult to address using conventional approaches. Furthermore, mRNA vaccines have shown promise in providing long-term immunity and can be tailored to a wide range of infectious diseases. This paper explores the advancements in mRNA vaccine research, challenges in distribution and acceptance, and the future potential of mRNA technology in vaccine development.